Reduced incidence of bony metastasis at initial prostate cancer diagnosis: Data from CaPSURE™

Ryan, Charles J.; Elkin, Eric P.; Small, Eric J.; Duchane, Janeen; Carroll, Peter

doi:10.1016/j.urolonc.2005.09.003

« Previous Next »Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 5 , Pages 396-402, September 2006

Reduced incidence of bony metastasis at initial prostate cancer diagnosis: Data from CaPSURE™☆

Charles J. Ryan, M.D.
- Department of Medicine, and UCSF Comprehensive Cancer Center, University of California–San Francisco, San Francisco, CA 94143, USA
- Corresponding author. Tel.: +1-415-353-9279; fax: +1-415-353-7779.
Eric P. Elkin, M.P.H.
- Department of Urology, and UCSF Comprehensive Cancer Center, University of California–San Francisco, San Francisco, CA 94143, USA
Eric J. Small, M.D.
- Department of Medicine, and UCSF Comprehensive Cancer Center, University of California–San Francisco, San Francisco, CA 94143, USA
Janeen Duchane, Ph.D.
- TAP Pharmaceutical Products, Inc., Lake Forest, IL 60045, USA
Peter Carroll, M.D.
- Department of Urology, and UCSF Comprehensive Cancer Center, University of California–San Francisco, San Francisco, CA 94143, USA

Received 12 July 2005; received in revised form 1 September 2005; accepted 2 September 2005.

To access this article, please choose from the options below

☆ CaPSURE™ is supported by TAP Pharmaceutical Products, Inc. (Lake Forest, IL). This research was additionally funded by the National Institutes of Health/National Cancer Institute University of California–San Francisco, SPORE—Special Program of Research Excellence p50c89520.